Peer Review History
Original SubmissionJune 17, 2021 |
---|
Transfer Alert
This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.
PONE-D-21-19890 Lymphopenia in hospitalized patients and its relationship with severity of illness and mortality. PLOS ONE Dear Dr. Andreu-Ballester, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 05 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Aleksandar R. Zivkovic Academic Editor PLOS ONE Journal requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer #1: This is an interesting manuscript that explores an under-appreciated aspect of routine laboratory studies in patients. It is a welcome addition to the literature. General comments: The manuscript at times does not quite make sense in English. I struggled to understand some parts of the paper. There are also several grammatical and spelling errors (e.g. in the abstract the first line says "mayor" when I believe the intent is "major"). Abstract: Rewrite the second sentence in the background. The current wording is confusing. There are also other spelling/grammatical errors (e.g. "mean time to dead" should probably be "mean time to death") Introduction: -In the first paragraph it mentions SIRS and states that includes criteria such as thrombocytopenia and neutrophilia. These are manifestations of sepsis but are not included in the SIRS definition. I would also include other criteria for sepsis (qSOFA, SOFA) in the introduction as well. -The second paragraph needs rephrasing as well. SIRS in it's current definition is well defined but the accuracy and clinical utility are called into question. I believe the intent the authors are trying to convey with this sentence is that sepsis itself is difficult to diagnose. -I recommend moving the definitions for SOI and ROM to the introduction from discussion. Methods: -Were these all patients or only adult patients? Results: -Again would revise some of the language to make the text more clear -Table 2 is a bit confusing. From my understanding each admission gets one diagnosis as the number of cases equals the number of admissions captured. It would be helpful to explain how they were coded as such given that many patients should have multiple reasons for hospitalization (i.e. having both a respiratory and circulatory system issue). -If feasible it would be interesting to compare lymphopenia in infectious diagnosis vs non-infectious diagnoses -For Table 2 what does the acronym "DD" stand for? -On page 8 why wwas 20 chosen as the days of lymphopenia? -On page 8 I am unsure what the first sentence of the third paragraph is trying to convey. I believe more days of lymphopenia are linked with worse prognosis but I am unsure as the figure is unlabeled. -In table 3 I think it would be beneficial if the significance was reported in leukopenia and neutropenia in the "bivariate analysis" given their inclusion in the multivariable analysis Discussion: -The first paragraph of page 10 needs to be revised heavily. I would also consider a citation of why lymphocytes are suppressed in sepsis -The definitions of APR-DRG, SOI, and DRG should be moved to the introduction -Why is lymphopenia during hospitalization more associated with mortality than lymphopenia on admission as show on page 8 and figure 2? -I am not sure that the phrase "very significant direct relationship" can be used in this context on page 10. I would discuss this with a statistician to determine the appropriate language. -On page 11 I do not think you can make the claim that "lymphopenia is clearly related to infectious pathology". Unless I missed it, the results do not specifically compare infectious vs non-infectious diagnoses so the authors do not know lymphopenia is more associated with sepsis. Figures: -Figure 1 needs the axes labeled on both x and y axes. It also needs a short explanation of what each table is describing -Figure 2c needs to have the axes labeled and also an explanation of what it is conveying -Figures 2D and 2E need to have the axes labeled and an explanation of what it is trying to convey Overall the data presented is interesting. My main issues with the manuscript is the clarity and language, all I believe can be addressed with further revision. Reviewer #2: Dear authors, this is a very interesting manuscript. I have some suggestions before publication: 1) In all tables you only provide information of the overall population and of the group of interest . However, to better understand the results it is important to provide the comparison group ( non limphopenia, patients who survived etc...) I presume that the p-value in these tables refer to the univariate logistic regressions. I believe that it would be more statistically sound to provide the univariate comparisons as descriptive statistics also for categorical variables (noun and %) using fisher test or qui- square test. Please add these comparisons to the statistical plan in the methods section and to the tables in the results section. 2)Please explain in the cox model which variable were included and provide (as supplement) the HR and CI for each adjusted variable. 3) Please explain further appendix S1. It is not clear to me what it represents for example 1 means that the patient only had one diagnosis within the disease subgroup? 4) The figures are very illustrative but please provide the individual p values of each comparison in figure 1. In figure 2 D and E I suggest that you provide the non limphopenia group as well and to compare both groups (limpohpenia in admission vs non limphopenia in admission and limphopenia during hospital stay and non limphopenia during hospital stay) providing a p value. 5) the manuscript needs English editing . for example in the abstract and in the introduction it is written mayor instead of major surgery . Also some sentences appear incomplete. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: Yes: Elisa Gouvêa Bogossian [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 1 |
Lymphopenia in hospitalized patients and its relationship with severity of illness and mortality. PONE-D-21-19890R1 Dear Dr. Andreu-Ballester, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Aleksandar R. Zivkovic Academic Editor PLOS ONE |
Formally Accepted |
PONE-D-21-19890R1 Lymphopenia in hospitalized patients and its relationship with severity of illness and mortality. Dear Dr. Andreu-Ballester: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Aleksandar R. Zivkovic Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .